CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Medical Director
Pyxis Oncology, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Clinic I Provincial
Barcelona, Spain
- H. Vall D'Hebron
Barcelona, Spain
- Hospital Quirón Dexeus
Barcelona, Spain
- H. Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain
- H. Lucus Augusti
Lugo, Spain
- H. Doce de Octubre
Madrid, Spain
- H. Hm Sanchinnarro
Madrid, Spain
- H. de Málaga
Málaga, Spain
- H. la Fe
Valencia, Spain
- H. General de Valencia
Valencia de Alcántara, Spain
- University of Arizona Cancer Center
Tucson, Arizona, United States
- City of Hope
Duarte, California, United States
- Yale University
New Haven, Connecticut, United States
- Hem-Onc Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (umgccc)
Baltimore, Maryland, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Suny Upstate Medical Hospital
Syracuse, New York, United States
- University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Fox Chase Center
Rockledge, Pennsylvania, United States
- Tennessee Oncology
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Jul 2017
- Primary completion
- 16 Nov 2020
- Completion
- 16 Nov 2020
- Last update posted
- 26 Dec 2023
- Registered enrollment
- 140
- Registry id
- NCT03123783
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.